Lenalidomide Mylan

Lenalidomide, the active ingredient in Lenalidomide Mylan, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple Myeloma: enhances progression‑free survival and overall response rates, particularly in patients with relapsed or refractory disease who have received prior therapies. - Myelodysplastic Syndromes with del(5q): decreases red‑cell transfusion requirements and can achieve cytogenetic remission, improving hematologic parameters in affected patients. - Mantle Cell Lymphoma: offers disease control and response in adults with relapsed or refractory mantle‑cell lymphoma after standard treatment options have failed.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness, sometimes with vomiting. - Rash: skin redness or irritation. - Constipation: difficulty passing stools. - Musculoskeletal pain: aches in muscles or joints.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Severe thrombocytopenia: low platelet count leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or liver injury.

Before initiating Lenalidomide therapy, several precautions should be considered to minimize risks.

- Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required for both patients and partners. - Thromboembolic prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal function: evaluate kidney function and adjust monitoring in patients with impairment. - Hepatic function: monitor liver enzymes, especially in patients with pre‑existing liver disease. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin, carbamazepine). - Anticoagulants: increased risk of bleeding when combined with warfarin or direct oral anticoagulants. - Immunosuppressants: heightened infection risk when used with high‑dose steroids or other immunosuppressive agents.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: may increase plasma levels (e.g., verapamil, quinidine). - Vaccines: live attenuated vaccines should be avoided due to immunomodulatory effects. - CYP450 substrates: monitor drugs metabolized by CYP enzymes for potential alterations.